Literature DB >> 24439238

Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial.

Beate Herpertz-Dahlmann1, Reinhild Schwarte2, Melanie Krei2, Karin Egberts3, Andreas Warnke3, Christoph Wewetzer4, Ernst Pfeiffer5, Christian Fleischhaker6, André Scherag7, Kristian Holtkamp8, Ulrich Hagenah2, Katharina Bühren2, Kerstin Konrad9, Ulrike Schmidt10, Carmen Schade-Brittinger11, Nina Timmesfeld12, Astrid Dempfle12.   

Abstract

BACKGROUND: In-patient treatment (IP) is the treatment setting of choice for moderately-to-severely ill adolescents with anorexia nervosa, but it is costly, and the risks of relapse and readmissions are high. Day patient treatment (DP) is less expensive and might avoid problems of relapse and readmission by easing the transition from hospital to home. We investigated the safety and efficacy of DP after short inpatient care compared with continued IP.
METHODS: For this multicentre, randomised, open-label, non-inferiority trial, we enrolled female patients (aged 11-18 years) with anorexia nervosa from six centres in Germany. Patients were eligible if they had a body-mass index (BMI) below the tenth percentile and it was their first admission to hospital for anorexia nervosa. We used a computer-generated randomisation sequence to randomly assign patients to continued IP or DP after 3 weeks of inpatient care (1:1; stratified for age and BMI at admission). The treatment programme and treatment intensity in both study groups were identical. The primary outcome was the increase in BMI between the time of admission and a 12-month follow-up adjusted for age and duration of illness (non-inferiority margin of 0·75 kg/m(2)). Analysis was done by modified intention to treat. This trial is registered with the International Standard Randomised Controlled Trial Number Register, number ISRCTN67783402, and the Deutsches Register Klinischer Studien, number DRKS00000101.
FINDINGS: Between Feb 2, 2007, to April 27, 2010, we screened 660 patients for eligibility, 172 of whom we randomly allocated to treatment: 85 to IP and 87 to DP. DP was non-inferior to IP with respect to the primary outcome, BMI at the 12-month follow-up (mean difference 0·46 kg/m(2) in favour of DP (95% CI, -0·11 to 1·02; pnon-inferiority<0·0001). The number of treatment-related serious adverse events was similar in both study groups (eight in the IP group, seven in the DP group). Three serious adverse events in the IP group and two in the DP group were related to suicidal ideation; one patient in the DP attempted suicide 3 months after she was discharged.
INTERPRETATION: DP after short inpatient care in adolescent patients with non-chronic anorexia nervosa seems no less effective than IP for weight restoration and maintenance during the first year after admission. Thus, DP might be a safe and less costly alternative to IP. Our results justify the broad implementation of this approach. FUNDING: German Ministry for Education and Research.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24439238     DOI: 10.1016/S0140-6736(13)62411-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  52 in total

1.  Identification of determinants of referral and follow-up body mass index of adolescent patients with anorexia nervosa: evidence for the role of premorbid body weight.

Authors:  Johannes Hebebrand
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-05       Impact factor: 4.785

Review 2.  Treating Eating Disorders at Higher Levels of Care: Overview and Challenges.

Authors:  Leslie K Anderson; Erin E Reilly; Laura Berner; Christina E Wierenga; Michelle D Jones; Tiffany A Brown; Walter H Kaye; Anne Cusack
Journal:  Curr Psychiatry Rep       Date:  2017-08       Impact factor: 5.285

3.  Treatment dropout in a family-based partial hospitalization program for eating disorders.

Authors:  Renee D Rienecke
Journal:  Eat Weight Disord       Date:  2018-07-19       Impact factor: 4.652

4.  Systematic review of evidence for different treatment settings in anorexia nervosa.

Authors:  Sloane Madden; Phillipa Hay; Stephen Touyz
Journal:  World J Psychiatry       Date:  2015-03-22

5.  The relationship between premorbid body weight and weight at referral, at discharge and at 1-year follow-up in anorexia nervosa.

Authors:  Manuel Föcker; Katharina Bühren; Nina Timmesfeld; Astrid Dempfle; Susanne Knoll; Reinhild Schwarte; Karin Maria Egberts; Ernst Pfeiffer; Christian Fleischhaker; Christoph Wewetzer; Johannes Hebebrand; Beate Herpertz-Dahlmann
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-08-27       Impact factor: 4.785

6.  From efficacy to effectiveness: comparing outcomes for youth with anorexia nervosa treated in research trials versus clinical care.

Authors:  Erin C Accurso; Ellen E Fitzsimmons-Craft; Anna C Ciao; Daniel Le Grange
Journal:  Behav Res Ther       Date:  2014-12-23

7.  Refeeding in anorexia nervosa.

Authors:  Anne Bargiacchi; Julia Clarke; Anne Paulsen; Juliane Leger
Journal:  Eur J Pediatr       Date:  2018-11-27       Impact factor: 3.183

8.  Combining day treatment and outpatient treatment for eating disorders: findings from a naturalistic setting.

Authors:  Ina Beintner; Kristian Hütter; Katrin Gramatke; Corinna Jacobi
Journal:  Eat Weight Disord       Date:  2019-01-31       Impact factor: 4.652

9.  Medical stabilization of adolescents with nutritional insufficiency: a clinical care path.

Authors:  Sarah E Strandjord; Erin H Sieke; Miranda Richmond; Arjun Khadilkar; Ellen S Rome
Journal:  Eat Weight Disord       Date:  2015-11-23       Impact factor: 4.652

10.  Health services utilization in patients with eating disorders: evidence from a cohort study in Emilia-Romagna.

Authors:  Antonella Piazza; Paola Rucci; Massimo Clo; Dino Gibertoni; Lucia Camellini; Marinella Di Stani; Maria Pia Fantini; Mila Ferri; Angelo Fioritti
Journal:  Eat Weight Disord       Date:  2016-09-29       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.